Biotech

All Articles

Analysts go into Avidity's DMD win, revealing nuances in data

.Avidity Biosciences amazed clients with phase 1/2 information in Duchenne muscular dystrophy (DMD) ...

Actinogen's cortisol blocker neglects period 2 depression research

.Actinogen Medical's cortisol blocker has actually skipped the major endpoint of a period 2 research...

Bivictrix makes a decision going exclusive only way to take ADC into clinic

.Antibody-drug conjugates (ADCs) have actually gone to the facility of lots of a billion-dollar biob...

TPG leadings up funds to $580M for assets all over life sciences

.Possession supervisor TPG, which has sustained biotechs like Sionna Rehabs and Santa Clam Ana Biogr...

Merck stops phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT plan has actually endured another problem. Months after shuttering a period ...

After a hard year, Exscientia folds up right into Recursion

.After a year determined through pipeline hairstyles, the departure of its own chief executive offic...

Cullinan, after $25M offer, restore bispecific to Harbour

.Cullinan Rehab was excited sufficient with Port BioMed's bispecific immune system activator that it...

A deeper take a look at Strong Biotech's Fierce 15

.Within this full week's episode of "The Best Line," our company're diving right into Intense Biotec...

Lilly encounters phase 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's party celebrating the commendation of Alzheimer's he...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of substantial management hirings, shootings...